Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 17/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.49 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.49 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.49 |
| ▸ | NPY4R | P50391 | 6/20 | 0.46 |
| ▸ | NPY2R | P49146 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31652650 | 0.92 | NPY1R (0.54) | NPY1RNPY5RNPFFR1NPFFR2NPY4R | |
| SCHEMBL31652837 | 0.91 | NPY1R (0.55) | NPY1RNPY5RNPFFR1NPFFR2 | |
| SCHEMBL31652734 | 0.91 | NPY1R (0.55) | NPY1RNPY5RNPFFR1NPFFR2 | |
| SCHEMBL31652820 | 0.91 | NPY1R (0.54) | NPY1RNPY5RNPFFR1NPFFR2NPY4R | |
| SCHEMBL31652623 | 0.90 | NPY1R (0.53) | NPY1RNPY5RNPFFR1NPFFR2 | |
| SCHEMBL31652720 | 0.90 | NPY1R (0.52) | NPY1RNPY5RNPFFR1NPFFR2NPY4R | |
| SCHEMBL31652652 | 0.88 | NPY1R (0.51) | NPY1RNPY5RNPFFR1NPFFR2NPY4R | |
| SCHEMBL31652661 | 0.87 | NPY1R (0.50) | NPY1RNPY5RNPFFR1NPFFR2NPY4R | |
| SCHEMBL31652535 | 0.87 | NPY1R (0.54) | NPY1RNPY5RNPFFR1NPFFR2NPY4R | |
| SCHEMBL31652559 | 0.87 | NPY1R (0.49) | NPY1RNPY5RNPFFR1NPFFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213735-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2025-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213735-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | NPY1R 1/4885NPY5R 4/4885NPFFR1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.